Stay updated on Nivolumab After SIRT for HCC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab After SIRT for HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab After SIRT for HCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study record regarding the safety and antitumoral efficacy of Nivolumab after SIRT for the treatment of patients with Hepatocellular Carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:09.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    17%
    Check dated 2024-05-22T20:56:29.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T21:58:08.000Z thumbnail image

Stay in the know with updates to Nivolumab After SIRT for HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab After SIRT for HCC Clinical Trial page.